Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 6
2005 16
2006 29
2007 26
2008 29
2009 32
2010 22
2011 32
2012 27
2013 22
2014 30
2015 33
2016 28
2017 20
2018 34
2019 34
2020 48
2021 40
2022 44
2023 20

Text availability

Article attribute

Article type

Publication date

Search Results

503 results

Results by year

Filters applied: . Clear all
Page 1
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. De Crescenzo F, et al. Lancet. 2022 Jul 16;400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9. Lancet. 2022. PMID: 35843245 Free article.
Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0.27-0.71 [moderate to very low]). Intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer discontinuations due to a …
Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0.27-0.71 [m …
Insomnia in Elderly Patients: Recommendations for Pharmacological Management.
Abad VC, Guilleminault C. Abad VC, et al. Drugs Aging. 2018 Sep;35(9):791-817. doi: 10.1007/s40266-018-0569-8. Drugs Aging. 2018. PMID: 30058034 Review.
This review focuses on Food and Drug Administration (FDA)-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs (eszopiclone, zolpidem, zaleplon), benzodiazepines (triazolam, temazepam), and ramelteon. We review the indications, dosing, efficacy, ben …
This review focuses on Food and Drug Administration (FDA)-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs (eszo …
Drugs for chronic insomnia.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Dec 17;60(1562):201-205. Med Lett Drugs Ther. 2018. PMID: 30625122 Review. No abstract available.
Melatonin.
Savage RA, Zafar N, Yohannan S, Miller JMM. Savage RA, et al. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30521244 Free Books & Documents.
Consequently, melatonin is not officially FDA-approved for any indication. However, melatonin receptor agonists such as ramelteon and tasimelteon are FDA-approved for the treatment of insomnia. ...
Consequently, melatonin is not officially FDA-approved for any indication. However, melatonin receptor agonists such as ramelteon and …
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.
Atkin T, Comai S, Gobbi G. Atkin T, et al. Pharmacol Rev. 2018 Apr;70(2):197-245. doi: 10.1124/pr.117.014381. Pharmacol Rev. 2018. PMID: 29487083 Review.
We analyzed the melatonergic agonist drugs, agomelatine, prolonged-release melatonin, ramelteon, and tasimelteon; the dual orexin receptor antagonist suvorexant; the modulators of the alpha(2)delta subunit of voltage-sensitive calcium channels, gabapentin and pregabalin; t …
We analyzed the melatonergic agonist drugs, agomelatine, prolonged-release melatonin, ramelteon, and tasimelteon; the dual orexin rec …
Menopause and Sleep Disorders.
Tandon VR, Sharma S, Mahajan A, Mahajan A, Tandon A. Tandon VR, et al. J Midlife Health. 2022 Jan-Mar;13(1):26-33. doi: 10.4103/jmh.jmh_18_22. Epub 2022 May 2. J Midlife Health. 2022. PMID: 35707298 Free PMC article. Review.
Tricyclic antidepressant, Selective Serotonin Reuptake Inhibitors (SSRI), Melatonin, Duloxetine, Fluoxetine, Imipramine, Nortriptyline or Amitriptyline and other drugs such as Eszopiclone, Escitalopram, Gabapentin, Quiteiapine, Citalopram, Mirtazapine followed by long-acting Mela …
Tricyclic antidepressant, Selective Serotonin Reuptake Inhibitors (SSRI), Melatonin, Duloxetine, Fluoxetine, Imipramine, Nortriptyline or Am …
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. Liu J, et al. Annu Rev Pharmacol Toxicol. 2016;56:361-83. doi: 10.1146/annurev-pharmtox-010814-124742. Epub 2015 Oct 23. Annu Rev Pharmacol Toxicol. 2016. PMID: 26514204 Free PMC article. Review.
This review describes the pharmacological properties of a slow-release melatonin preparation (i.e., Circadin) and synthetic ligands (i.e., agomelatine, ramelteon, tasimelteon), with emphasis on identifying specific therapeutic effects mediated through MT1 and MT2 receptor …
This review describes the pharmacological properties of a slow-release melatonin preparation (i.e., Circadin) and synthetic ligands (i.e., a …
Review of Safety and Efficacy of Sleep Medicines in Older Adults.
Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, Mergenhagen KA. Schroeck JL, et al. Clin Ther. 2016 Nov;38(11):2340-2372. doi: 10.1016/j.clinthera.2016.09.010. Epub 2016 Oct 15. Clin Ther. 2016. PMID: 27751669 Review.
Search terms included medications approved by the US Food and Drug Administration for insomnia: benzodiazepines (triazolam, estazolam, temazepam, flurazepam, and quazepam), nonbenzodiazepine receptor agonists (non-BzRAs; zaleplon, zolpidem, and eszopiclone), suvorexant, ramelt …
Search terms included medications approved by the US Food and Drug Administration for insomnia: benzodiazepines (triazolam, estazolam, temaz …
Melatonin for delirium prevention in hospitalized patients: A systematic review and meta-analysis.
Khaing K, Nair BR. Khaing K, et al. J Psychiatr Res. 2021 Jan;133:181-190. doi: 10.1016/j.jpsychires.2020.12.020. Epub 2020 Dec 13. J Psychiatr Res. 2021. PMID: 33348252
This systematic review and meta-analysis explores the effect of melatonin and melatonin receptor agonist, ramelteon on delirium prevention in adult hospitalized patients. METHODS: Randomized Controlled trials of melatonin/ramelteon published up to May 7, 2020 were i …
This systematic review and meta-analysis explores the effect of melatonin and melatonin receptor agonist, ramelteon on delirium preve …
Circadian Rhythm and Melatonin in the Treatment of Depression.
Satyanarayanan SK, Su H, Lin YW, Su KP. Satyanarayanan SK, et al. Curr Pharm Des. 2018;24(22):2549-2555. doi: 10.2174/1381612824666180803112304. Curr Pharm Des. 2018. PMID: 30073921 Review.
RESULTS: Melatonin, a pleiotropic regulator molecule and its analogues (ramelteon, agomelatine, TIK-301, Neu- P11 and tasimelteon) have been observed to resynchronize the circadian rhythm and some were said to alleviate depressive symptoms in depressed subjects. ...
RESULTS: Melatonin, a pleiotropic regulator molecule and its analogues (ramelteon, agomelatine, TIK-301, Neu- P11 and tasimelteon) ha …
503 results